Posted by Michael Wonder on 29 Jan 2018
Swissmedic accepts our filing for edaravone to treat ALS
23 January 2018 - Mitsubishi Tanabe Pharma Corporation announced today that the Swissmedic has accepted its filing for edaravone, an intravenous treatment for amyotrophic lateral sclerosis, a rapidly progressive neurological disease on 22 December 2017.
Mitsubishi Tanabe Pharma accomplished the clinical research program in patients diagnosed with amyotropic lateral sclerosis (ALS) in Japan. Edaravone was approved for use as a treatment for ALS in Japan, June 2015, South Korea, December 2015 and the U.S., May 2017.
